Startseite - Psoriasis-News

OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- Gestern 00:001 Tag
- 0 Antworten
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- Gestern 00:001 Tag
- 0 Antworten
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- Dienstag 00:002 Tage
- 0 Antworten
Keratinocyte FABP5 mediates saturated fat-induced MAPK/CCL20 signaling in psoriatic inflammation
Keratinocyte FABP5 mediates saturated fat-induced MAPK/CCL20 signaling in psoriatic inflammation

ein Artikel von Redaktion in PubMed
- Sonntag 11:004 Tage
- 0 Antworten
Development of a tool to measure patient-oriented outcomes for Veterans with inflammatory arthritis initiating self-administered biologic therapies
Development of a tool to measure patient-oriented outcomes for Veterans with inflammatory arthritis initiating self-administered biologic therapies

ein Artikel von Redaktion in PubMed
- Sonntag 11:004 Tage
- 0 Antworten
Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study
Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study

ein Artikel von Redaktion in PubMed
- Sonntag 11:004 Tage
- 0 Antworten
An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy and Durability of Response to ESK-001 (ONWARD3)
An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy and Durability of Response to ESK-001 (ONWARD3)

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- Samstag 00:005 Tage
- 0 Antworten
Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study
Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

ein Artikel von Redaktion in PubMed
- 6. November6. Nov
- 0 Antworten
Firearm Injury Prevention Bystander Intervention for Adolescents in Shooting Sports: A Cluster Randomized Clinical Trial
Firearm Injury Prevention Bystander Intervention for Adolescents in Shooting Sports: A Cluster Randomized Clinical Trial

ein Artikel von Redaktion in PubMed
- 6. November6. Nov
- 0 Antworten
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- 5. November5. Nov
- 0 Antworten
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- 5. November5. Nov
- 0 Antworten
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- 4. November4. Nov
- 0 Antworten
Dermoscopy vs. histopathology in palmoplantar psoriasis and hyperkeratotic eczema: a cross-sectional study
Dermoscopy vs. histopathology in palmoplantar psoriasis and hyperkeratotic eczema: a cross-sectional study

ein Artikel von Redaktion in PubMed
- 3. November3. Nov
- 0 Antworten
CGRP levels in autoimmune diseases: a systematic review and meta-analysis of its potential role as a biomarker
CGRP levels in autoimmune diseases: a systematic review and meta-analysis of its potential role as a biomarker

ein Artikel von Redaktion in PubMed
- 3. November3. Nov
- 0 Antworten
Immunomodulatory Probiotics in Psoriasis: Effects on the Gut-Skin-Immune Crosstalk and Systemic Inflammation: Immunomodulatory Probiotics and Psoriasis Disease
Immunomodulatory Probiotics in Psoriasis: Effects on the Gut-Skin-Immune Crosstalk and Systemic Inflammation: Immunomodulatory Probiotics and Psoriasis Disease

ein Artikel von Redaktion in PubMed
- 3. November3. Nov
- 0 Antworten
Integrated Transcriptomic and Single-Cell RNA Sequencing Analyses Identify Shared Inflammation-Related Candidate Genes in Psoriasis and Acute Myocardial Infarction
Integrated Transcriptomic and Single-Cell RNA Sequencing Analyses Identify Shared Inflammation-Related Candidate Genes in Psoriasis and Acute Myocardial Infarction

ein Artikel von Redaktion in PubMed
- 3. November3. Nov
- 0 Antworten
Integrative Analysis of Epidermal Barrier Dysfunction Regulators in Psoriasis
Integrative Analysis of Epidermal Barrier Dysfunction Regulators in Psoriasis

ein Artikel von Redaktion in PubMed
- 3. November3. Nov
- 0 Antworten
Localized IDO Delivery via Granular PEG Hydrogel Enhances Therapeutic Control of Psoriasis
Localized IDO Delivery via Granular PEG Hydrogel Enhances Therapeutic Control of Psoriasis

ein Artikel von Redaktion in PubMed
- 2. November2. Nov
- 0 Antworten
Targeting the IL-23 pathway in inflammatory bowel disease: from cytokine inhibition to oral IL-23 receptor blockade
Targeting the IL-23 pathway in inflammatory bowel disease: from cytokine inhibition to oral IL-23 receptor blockade

ein Artikel von Redaktion in PubMed
- 2. November2. Nov
- 0 Antworten
The Value of Systemic Inflammatory Parameters (Neutrophil-Lymphocyte Ratio and C-Reactive Protein) Combined with Psoriasis Area Severity Index in Predicting the Development of Arthritic Symptoms in Patients with Psoriasis
The Value of Systemic Inflammatory Parameters (Neutrophil-Lymphocyte Ratio and C-Reactive Protein) Combined with Psoriasis Area Severity Index in Predicting the Development of Arthritic Symptoms in Patients with Psoriasis

ein Artikel von Redaktion in PubMed
- 2. November2. Nov
- 0 Antworten

Letzte Aktivitäten

OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1

OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1

An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

Keratinocyte FABP5 mediates saturated fat-induced MAPK/CCL20 signaling in psoriatic inflammation

Development of a tool to measure patient-oriented outcomes for Veterans with inflammatory arthritis initiating self-administered biologic therapies

Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study

An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy and Durability of Response to ESK-001 (ONWARD3)

Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

Firearm Injury Prevention Bystander Intervention for Adolescents in Shooting Sports: A Cluster Randomized Clinical Trial

A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)

A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque

Dermoscopy vs. histopathology in palmoplantar psoriasis and hyperkeratotic eczema: a cross-sectional study

CGRP levels in autoimmune diseases: a systematic review and meta-analysis of its potential role as a biomarker

Immunomodulatory Probiotics in Psoriasis: Effects on the Gut-Skin-Immune Crosstalk and Systemic Inflammation: Immunomodulatory Probiotics and Psoriasis Disease

Integrated Transcriptomic and Single-Cell RNA Sequencing Analyses Identify Shared Inflammation-Related Candidate Genes in Psoriasis and Acute Myocardial Infarction

Integrative Analysis of Epidermal Barrier Dysfunction Regulators in Psoriasis

Localized IDO Delivery via Granular PEG Hydrogel Enhances Therapeutic Control of Psoriasis

Targeting the IL-23 pathway in inflammatory bowel disease: from cytokine inhibition to oral IL-23 receptor blockade

The Value of Systemic Inflammatory Parameters (Neutrophil-Lymphocyte Ratio and C-Reactive Protein) Combined with Psoriasis Area Severity Index in Predicting the Development of Arthritic Symptoms in Patients with Psoriasis

Konto

Navigation

Suche

Browser-Push-Nachrichten konfigurieren

Chrome (Android)

Chrome (Desktop)

Safari (iOS 16.4+)

Safari (macOS)

Edge (Android)

Edge (Desktop)

Firefox (Android)

Firefox (Desktop)